Calithera Biosciences to Present First Clinical Data from Development Program for Arginase Inhibitor CB-280 at NACFC 2021
21 oct. 2021 08h00 HE
|
Calithera Biosciences, Inc.
SOUTH SAN FRANCISCO, Calif., Oct. 21, 2021 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical-stage biopharmaceutical company, today announced that data from its Phase 1b...
Calithera Expands Oncology Pipeline with Acquisition of Two Clinical-Stage Assets from Takeda Pharmaceuticals
18 oct. 2021 16h07 HE
|
Calithera Biosciences, Inc.
-- TORC 1/2 inhibitor sapanisertib and SYK inhibitor mivavotinib strengthen Company’s precision oncology pipeline -- -- Calithera will initiate Phase 2 clinical trials of sapanisertib and mivavotinib...
Calithera Biosciences to Present Telaglenastat KEAPSAKE Trial in Progress Poster at the IASLC 2021 World Conference on Lung Cancer
08 sept. 2021 07h00 HE
|
Calithera Biosciences, Inc.
SOUTH SAN FRANCISCO, Calif., Sept. 08, 2021 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical stage biotechnology company focused on discovering and developing novel...
Calithera Biosciences to Participate in Two Upcoming Investor Conferences
02 sept. 2021 07h00 HE
|
Calithera Biosciences, Inc.
SOUTH SAN FRANCISCO, Calif., Sept. 02, 2021 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: CALA), a fully-integrated clinical stage biotechnology company focused on discovering and...
Calithera Biosciences Reports Second Quarter 2021 Financial Results and Recent Highlights
05 août 2021 16h05 HE
|
Calithera Biosciences, Inc.
-- Cash, Cash Equivalents and Investments Totaled $92.2 million as of June 30, 2021 -- -- Conference Call and Webcast Scheduled for 2:00 p.m. PT on August 5, 2021-- SOUTH SAN FRANCISCO, Calif., Aug....
Calithera Biosciences to Report Second Quarter 2021 Financial Results on Thursday, August 5, 2021
29 juil. 2021 07h00 HE
|
Calithera Biosciences, Inc.
SOUTH SAN FRANCISCO, Calif., July 29, 2021 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: CALA), a fully-integrated clinical-stage biotechnology company focused on discovering and...
Final Data from Calithera Biosciences’ Phase 2 CANTATA Study in Renal Cell Carcinoma Presented at 2021 ASCO Annual Meeting
07 juin 2021 08h00 HE
|
Calithera Biosciences, Inc.
SOUTH SAN FRANCISCO, Calif., June 07, 2021 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical-stage biotechnology company focused on discovering and developing novel...
Calithera to Present at the Jefferies 2021 Virtual Healthcare Conference
27 mai 2021 07h00 HE
|
Calithera Biosciences, Inc.
SOUTH SAN FRANCISCO, Calif., May 27, 2021 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical-stage biotechnology company focused on discovering and developing novel small...
Calithera Biosciences and Antengene Enter Worldwide License Agreement for Development & Commercialization of CB-708
17 mai 2021 08h00 HE
|
Calithera Biosciences, Inc.
--CB-708 is an oral small molecule inhibitor of CD73 in preclinical development for oncology--Antengene is granted exclusive rights to develop and commercialize asset discovered and initially...
Calithera Biosciences Reports First Quarter 2021 Financial Results and Recent Highlights
06 mai 2021 16h05 HE
|
Calithera Biosciences, Inc.
--$102.9 Million in Cash and Investments at March 31, 2021-- -- Conference Call and Webcast Scheduled for 2:00 p.m. PT on May 6, 2021-- SOUTH SAN FRANCISCO, Calif., May 06, 2021 (GLOBE...